Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845204 | 0.89 | GNRHR (0.44) | TP53GNRHRMEN1KMT2AFAAH | |
| SCHEMBL22845483 | 0.83 | GNRHR (0.44) | TP53GNRHRMEN1KMT2AFAAH | |
| SCHEMBL22845227 | 0.83 | GNRHR (0.44) | TP53GNRHRMEN1KMT2AMAPT | |
| SCHEMBL22845269 | 0.79 | GNRHR (0.43) | TP53LMNAGNRHRMEN1KMT2A | |
| SCHEMBL22845374 | 0.79 | GNRHR (0.45) | GNRHRMEN1KMT2AMAPTACHE | |
| SCHEMBL22845396 | 0.78 | GNRHR (0.44) | GNRHRMEN1KMT2AMAPTACHE | |
| SCHEMBL22845409 | 0.75 | TSHR (0.40) | TP53LMNAMAPTPOLBALDH1A1 | |
| SCHEMBL22845489 | 0.75 | GNRHR (0.44) | LMNAGNRHRMEN1KMT2AMAPT | |
| SCHEMBL22845408 | 0.74 | ALDH1A1 (0.43) | KMT2AMAPTALDH1A1 | |
| SCHEMBL22845307 | 0.71 | CLPP (0.47) | LMNAGNRHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | TP53 1710/4885LMNA 1680/4885GNRHR 2198/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | TP53 1710/4885LMNA 1680/4885GNRHR 2198/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | TP53 1710/4885LMNA 1680/4885GNRHR 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.